Combretastatin analogs of the antitumor agent tubuloclustin N-[7-(adamant-2-yloxy)-7-oxoheptanoyl]-Ndeacetylcolchicine} were prepared via esterification of combretastatin by monoesters of pimelic or adipic acid with adamantan-2-ol or (adamantan-1-yl)methanol. These conjugates were stable and cytotoxic to human lung carcinoma A549 cells (EC50 ≈ 50 – 70 nM) and caused depolymerization of microtubules and slight clustering of tubulin. Tubuloclustin analogs with shortened linkers were prepared via amidation by N-deacetylcolchicine of monoesters of adipic or succinic acids with adamantan-1-ol or (adamantan-1-yl)methanol. The conjugate N-[6-(adamantyl)-6-oxohexanoyl]-N-deacetylcolchicine was more active (EC50 ≈ 4 nM) than tubuloclustin and promoted strong tubulin clusterization. All compounds induced apoptosis of A549 cells. Tests in vivo of N-[6-(adamantyl)-6-oxoheaxnoyl]-N-deacetylcolchicine on carcinoma A549 experimental models were concluded to be promising.
抗肿瘤药物Tubuloclustin的Combretastatin类似物N-[7-(
氟烯-2-氧基)-7-氧代庚酰]-N-去
乙酸科克铃}是通过将Combretastatin与含有
氟烯-2-醇或(
氟烯-1-基)
甲醇的
庚酸单酯或
戊酸单酯进行酯化制备的。这些结合物稳定且对人肺癌A549细胞具有细胞毒性(
EC50 ≈ 50 – 70 nM),并导致微管去聚合及微管蛋白的轻微聚集。通过将去乙酰科克铃与含有
氟烯-1-醇或(
氟烯-1-基)
甲醇的
戊酸或
琥珀酸单酯进行酰胺化,制备了短链接头的Tubuloclustin类似物。结合物N-[6-(
氟烯基)-6-氧代己酰]-N-去
乙酸科克铃的活性比Tubuloclustin更强(
EC50 ≈ 4 nM),并促进了显著的微管蛋白聚集。所有化合物均诱导A549细胞的凋亡。在A549癌症实验模型中对N-[6-(
氟烯基)-6-氧代己酰]-N-去
乙酸科克铃的体内测试结果被认为是有前景的。